Company / Accounts Receivable
Corcept Therapeutics Incorporated Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$59.8M
FY2025
5-year range
$27.6M / $59.8M
FY2021-FY2025
Trend
+10.8%
vs FY2024
Sector context
#65 of 115
Health Care
What the data says
At $60M, Corcept Therapeutics Incorporated's accounts receivable ranks #65 of 115 in the Health Care sector. Accounts Receivable has increased for 9 consecutive years, from $10M in FY2016 to $60M in FY2025.
Based on SEC 10-K filings.
$60M in FY2025 with a 5-year CAGR of +17.9%.
Improved from $41M to $60M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +24.4%
- 5-Year CAGR
- +17.9%
- 10-Year CAGR
- -
Sector benchmark
#65 of 115 in Health CareTop 57% of 115This company $59.8M Sector average $1.1B
▼
-94.7% below sector average
Key checks
Key Insights
- Corcept Therapeutics Incorporated's accounts receivable has grown for 9 consecutive years.
- 5-year CAGR of +17.9%, indicating consistent growth.
- In FY2025, accounts receivable increased 10.8% year-over-year.
- Ranks #65 out of 115 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.44 (safe zone, above 2.9 threshold)
- Strong profit margin: 20.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $59.8M | +10.8% |
| FY2024 | $54.0M | +31.3% |
| FY2023 | $41.1M | +32.4% |
| FY2022 | $31.1M | +12.4% |
| FY2021 | $27.6M | +5.4% |
| FY2020 | $26.2M | +31.5% |
| FY2019 | $19.9M | +13.3% |
| FY2018 | $17.6M | +15.0% |
| FY2017 | $15.3M | +55.2% |
| FY2016 | $9.9M | +58.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026